tiprankstipranks
Castle Biosciences (CSTL)
NASDAQ:CSTL
US Market
CSTL
Castle Biosciences
RESEARCH TOOLSreports
Want to see CSTL full AI Analyst Report?

Castle Biosciences (CSTL) Stock Forecast & Price Target

461 Followers
See the Price Targets and Ratings of:

CSTL Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Castle
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CSTL Stock 12 Month Forecast

Average Price Target

$44.40
▲(77.25% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Castle Biosciences in the last 3 months. The average price target is $44.40 with a high forecast of $52.00 and a low forecast of $40.00. The average price target represents a 77.25% change from the last price of $25.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","23":"$23","33":"$33","43":"$43","53":"$53"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,23,33,43,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.81,26.90153846153846,28.99307692307692,31.084615384615383,33.176153846153845,35.26769230769231,37.35923076923077,39.450769230769225,41.54230769230769,43.63384615384615,45.72538461538461,47.816923076923075,49.90846153846154,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.81,26.316923076923075,27.82384615384615,29.330769230769228,30.837692307692308,32.34461538461538,33.85153846153846,35.35846153846154,36.86538461538461,38.372307692307686,39.879230769230766,41.386153846153846,42.89307692307692,{"y":44.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.81,25.978461538461538,27.146923076923077,28.315384615384616,29.48384615384615,30.652307692307694,31.82076923076923,32.98923076923077,34.15769230769231,35.326153846153844,36.494615384615386,37.66307692307692,38.831538461538464,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.27,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.02,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.47,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.99,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.05,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.81,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$52.00Average Price Target$44.40Lowest Price Target$40.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG Analyst forecast on CSTL
Mark Massaro
BTIG
BTIG
$50→$40
Buy
59.68%
Upside
Reiterated
05/13/26
Castle Biosciences: Buy Reiterated on Strong Q1 Execution and Undervalued Growth Potential Despite Price Target Trim to $40
Robert W. Baird Analyst forecast on CSTL
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$44→$43
Buy
71.66%
Upside
Reiterated
05/07/26
Carlisle price target lowered to $43 from $44 at BairdCarlisle price target lowered to $43 from $44 at Baird
Guggenheim Analyst forecast on CSTL
Subbu Nambi
Guggenheim
Guggenheim
$47
Buy
87.62%
Upside
Reiterated
05/07/26
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), BioCryst (BCRX)
Lake Street Analyst forecast on CSTL
Thomas Flaten
Lake Street
Lake Street
$52
Buy
107.58%
Upside
Reiterated
05/07/26
Castle Biosciences (CSTL) Gets a Buy from Lake Street
Canaccord Genuity Analyst forecast on CSTL
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$40
Buy
59.68%
Upside
Reiterated
05/06/26
Castle Biosciences: Buy Rating Reiterated as Strong Q1, Raised 2026 Outlook and Unchanged $40 Price Target Underscore Undervaluation
KeyBanc Analyst forecast on CSTL
Paul Knight
KeyBanc
KeyBanc
$36→$50
Buy
99.60%
Upside
Reiterated
01/29/26
Castle Biosciences price target raised to $50 from $36 at KeyBancCastle Biosciences price target raised to $50 from $36 at KeyBanc
Leerink Partners Analyst forecast on CSTL
Puneet Souda
Leerink Partners
Leerink Partners
$35
Buy
39.72%
Upside
Reiterated
08/05/25
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Castle Biosciences (NASDAQ: CSTL) and Regeneron (NASDAQ: REGN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG Analyst forecast on CSTL
Mark Massaro
BTIG
BTIG
$50→$40
Buy
59.68%
Upside
Reiterated
05/13/26
Castle Biosciences: Buy Reiterated on Strong Q1 Execution and Undervalued Growth Potential Despite Price Target Trim to $40
Robert W. Baird Analyst forecast on CSTL
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$44→$43
Buy
71.66%
Upside
Reiterated
05/07/26
Carlisle price target lowered to $43 from $44 at BairdCarlisle price target lowered to $43 from $44 at Baird
Guggenheim Analyst forecast on CSTL
Subbu Nambi
Guggenheim
Guggenheim
$47
Buy
87.62%
Upside
Reiterated
05/07/26
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), BioCryst (BCRX)
Lake Street Analyst forecast on CSTL
Thomas Flaten
Lake Street
Lake Street
$52
Buy
107.58%
Upside
Reiterated
05/07/26
Castle Biosciences (CSTL) Gets a Buy from Lake Street
Canaccord Genuity Analyst forecast on CSTL
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$40
Buy
59.68%
Upside
Reiterated
05/06/26
Castle Biosciences: Buy Rating Reiterated as Strong Q1, Raised 2026 Outlook and Unchanged $40 Price Target Underscore Undervaluation
KeyBanc Analyst forecast on CSTL
Paul Knight
KeyBanc
KeyBanc
$36→$50
Buy
99.60%
Upside
Reiterated
01/29/26
Castle Biosciences price target raised to $50 from $36 at KeyBancCastle Biosciences price target raised to $50 from $36 at KeyBanc
Leerink Partners Analyst forecast on CSTL
Puneet Souda
Leerink Partners
Leerink Partners
$35
Buy
39.72%
Upside
Reiterated
08/05/25
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Castle Biosciences (NASDAQ: CSTL) and Regeneron (NASDAQ: REGN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Castle Biosciences

3 Months
Kyle Mikson CFACanaccord Genuity
Success Rate
12/26 ratings generated profit
46%
Average Return
+4.63%
Copying Kyle Mikson CFA's trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of +4.63% per trade.
1 Year
Mark MassaroBTIG
Success Rate
11/22 ratings generated profit
50%
Average Return
-3.80%
Copying Mark Massaro's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -3.80% per trade.
2 Years
Catherine Ramsey SchulteRobert W. Baird
Success Rate
18/41 ratings generated profit
44%
Average Return
-0.10%
Copying Catherine Ramsey Schulte's trades and holding each position for 2 Years would result in 43.90% of your transactions generating a profit, with an average return of -0.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CSTL Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
2
3
4
7
Buy
10
9
7
2
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
11
10
6
7
In the current month, CSTL has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CSTL average Analyst price target in the past 3 months is 44.40.
Each month's total comprises the sum of three months' worth of ratings.

CSTL Financial Forecast

CSTL Earnings Forecast

Next quarter’s earnings estimate for CSTL is -$0.40 with a range of -$0.53 to -$0.30. The previous quarter’s EPS was -$0.49. CSTL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CSTL has Performed in-line its overall industry.
Next quarter’s earnings estimate for CSTL is -$0.40 with a range of -$0.53 to -$0.30. The previous quarter’s EPS was -$0.49. CSTL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CSTL has Performed in-line its overall industry.

CSTL Sales Forecast

Next quarter’s sales forecast for CSTL is $86.26M with a range of $85.00M to $88.10M. The previous quarter’s sales results were $83.68M. CSTL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CSTL has Performed in-line its overall industry.
Next quarter’s sales forecast for CSTL is $86.26M with a range of $85.00M to $88.10M. The previous quarter’s sales results were $83.68M. CSTL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CSTL has Performed in-line its overall industry.

CSTL Stock Forecast FAQ

What is CSTL’s average 12-month price target, according to analysts?
Based on analyst ratings, Castle Biosciences’s 12-month average price target is 44.40.
    What is CSTL’s upside potential, based on the analysts’ average price target?
    Castle Biosciences has 77.25% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CSTL a Buy, Sell or Hold?
          Castle Biosciences has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Castle Biosciences’s price target?
            The average price target for Castle Biosciences is 44.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $52.00 ,the lowest forecast is $40.00. The average price target represents 77.25% Increase from the current price of $25.05.
              What do analysts say about Castle Biosciences?
              Castle Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of CSTL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.